ImaRx's SonoLysis begins phase I/II PAOD trial

Pharmaceutical developer ImaRx Therapeutics said the first patient has been treated in a new phase I/II clinical trial evaluating the safety and effectiveness of its SonoLysis product for the treatment of peripheral arterial occlusive disease (PAOD).

SonoLysis combines external ultrasound and ImaRx's proprietary nanobubble technology to clear blood clots. The 12-patient multicenter trial will include six patients receiving a 60-minute treatment of SonoLysis (nanobubbles and ultrasound), while the remaining six will receive SonoLysis in conjunction with a small bolus of tPA, a lytic agent administered to dissolve the blood clots that cause PAOD, according to the Tucson, AZ-based firm.

By staff writers
April 12, 2005

Related Reading

ImaRx initiates SonoLysis phase II stroke trial, April 5, 2005

ImaRx raises $7 million, March 10, 2005

ImaRx, Guerbet in MR molecular imaging deal, December 10, 2004

ImaRx completes private placement, names chairman, April 2, 2004

ImaRx inks licensing deal, November 19, 2003

Copyright © 2005

Page 1 of 509
Next Page